Bouvel Investment Partners, LLC Dexcom Inc Transaction History

Bouvel Investment Partners, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 14, 2023	BUY	$112.47 - $130.98 $41,276 - $48,069	367 Added 2.36%	15,901 $2.04 Million
Q1 2023 Apr 11, 2023	BUY	$104.0 - $122.92 $45,968 - $54,330	442 Added 2.93%	15,534 $1.8 Million
Q4 2022 Jan 18, 2023	BUY	$84.98 - $122.67 $40,790 - $58,881	480 Added 3.28%	15,092 $0
Q3 2022 Oct 13, 2022	BUY	$76.35 - $94.18 $10,689 - $13,185	140 Added 0.97%	14,612 $1.18 Million
Q2 2022 Jul 13, 2022	BUY	$67.99 - $132.89 $741,634 - $1.45 Million	10,908 Added 306.06%	14,472 $1.08 Million
Q1 2022 Apr 11, 2022	BUY	$94.08 - $130.2 $3,104 - $4,296	33 Added 0.93%	3,564 $1.82 Million
Q4 2021 Jan 19, 2022	SELL	$129.87 - $162.82 $10,909 - $13,676	-84 Reduced 2.32%	3,531 $1.9 Million
Q3 2021 Oct 07, 2021	SELL	$106.71 - $143.18 $7,576 - $10,165	-71 Reduced 1.93%	3,615 $1.98 Million
Q2 2021 Jul 12, 2021	BUY	$80.99 - $107.93 $647 - $863	8 Added 0.22%	3,686 $1.57 Million
Q1 2021 Apr 16, 2021	SELL	$84.79 - $104.74 $1,187 - $1,466	-14 Reduced 0.38%	3,678 $1.32 Million
Q4 2020 Feb 02, 2021	BUY	$78.0 - $104.5 $287,976 - $385,814	3,692 New	3,692 $1.37 Million

1,035

353M

5.51M

5.61M

Ticker DXCM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 386,257,984
Market Cap $34.3B
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...

Get notified when there are updates to the investment portfolio of Bouvel Investment Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Bouvel Investment Partners, LLC with notifications on news.